nach oben

Alzheimer's Research & Therapy

Erschienen in:

01.02.2014 | Review

Fyn kinase inhibition as a novel therapy for Alzheimer’s disease

verfasst von: Haakon B Nygaard, Christopher H van Dyck, Stephen M Strittmatter

Erschienen in: Alzheimer's Research & Therapy | Ausgabe 1/2014

Einloggen, um Zugang zu erhalten

Abstract

Alzheimer’s disease (AD) is a devastating neurodegenerative disorder, afflicting more than one-third of people over the age of 85. While many therapies for AD are in late-stage clinical testing, rational drug design based on distinct signaling pathways in this disorder is only now emerging. Here we review the putative signaling pathway of amyloid-beta (Aβ), by which the tyrosine kinase Fyn is activated via cell surface binding of Aβ oligomers to cellular prion protein. Several lines of evidence implicate Fyn in the pathogenesis of AD, and its interaction with both Aβ and Tau renders Fyn a unique therapeutic target that addresses both of the major pathologic hallmarks of AD. We are currently enrolling patients in a phase Ib study of saracatinib (AZD0530), a small molecule inhibitor with high potency for Src and Fyn, for the treatment of AD. The results of this trial and a planned phase IIa multisite study will provide important data regarding the potential for this therapeutic strategy in AD.

Nur mit Berechtigung zugänglich

Lauren J, Gimbel DA, Nygaard HB, Gilbert JW, Strittmatter SM: Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers. Nature. 2009, 457: 1128-1132. 10.1038/nature07761.PubMedCentralCrossRefPubMed

Um JW, Nygaard HB, Heiss JK, Kostylev MA, Stagi M, Vortmeyer A, Wisniewski T, Gunther EC, Strittmatter SM: Alzheimer amyloid-beta oligomer bound to postsynaptic prion protein activates Fyn to impair neurons. Nat Neurosci. 2012, 15: 1227-1235. 10.1038/nn.3178.PubMedCentralCrossRefPubMed

Um JW, Kaufman AC, Kostylev M, Heiss JK, Stagi M, Takahashi H, Kerrisk ME, Vortmeyer A, Wisniewski T, Koleske AJ, Gunther EC, Nygaard HB, Strittmatter SM: Metabotropic glutamate receptor 5 is a coreceptor for Alzheimer Aβ oligomer bound to cellular prion protein. Neuron. 2013, 79: 887-902. 10.1016/j.neuron.2013.06.036.PubMedCentralCrossRefPubMed

Larson M, Sherman MA, Amar F, Nuvolone M, Schneider JA, Bennett DA, Aguzzi A, Lesne SE: The complex PrP(c)–Fyn couples human oligomeric Aβ with pathological tau changes in Alzheimer’s disease. J Neurosci. 2012, 32: 16857a-16871a. 10.1523/JNEUROSCI.1858-12.2012.CrossRef

Thomas SM, Brugge JS: Cellular functions regulated by Src family kinases. Annu Rev Cell Dev Biol. 1997, 13: 513-609. 10.1146/annurev.cellbio.13.1.513.CrossRefPubMed

Martin GS: The hunting of the Src. Nat Rev Mol Cell Biol. 2001, 2: 467-475. 10.1038/35073094.CrossRefPubMed

Boggon TJ, Eck MJ: Structure and regulation of Src family kinases. Oncogene. 2004, 23: 7918-7927. 10.1038/sj.onc.1208081.CrossRefPubMed

Sicheri F, Kuriyan J: Structures of Src-family tyrosine kinases. Curr Opin Struct Biol. 1997, 7: 777-785. 10.1016/S0959-440X(97)80146-7.CrossRefPubMed

Jelic D, Mildner B, Kostrun S, Nujic K, Verbanac D, Culic O, Antolovic R, Brandt W: Homology modeling of human Fyn kinase structure: discovery of rosmarinic acid as a new Fyn kinase inhibitor and in silico study of its possible binding modes. J Med Chem. 2007, 50: 1090-1100. 10.1021/jm0607202.CrossRefPubMed

10.

Yang K, Belrose J, Trepanier CH, Lei G, Jackson MF, MacDonald JF: Fyn, a potential target for Alzheimer’s disease. J Alzheimers Dis. 2011, 27: 243-252.PubMed

11.

Goldsmith JF, Hall CG, Atkinson TP: Identification of an alternatively spliced isoform of the fyn tyrosine kinase. Biochem Biophys Res Commun. 2002, 298: 501-504. 10.1016/S0006-291X(02)02510-X.CrossRefPubMed

12.

Cooke MP, Perlmutter RM: Expression of a novel form of the fyn proto-oncogene in hematopoietic cells. New Biol. 1989, 1: 66-74.PubMed

13.

Kramer-Albers EM, White R: From axon-glial signalling to myelination: the integrating role of oligodendroglial Fyn kinase. Cell Mol Life Sci. 2011, 68: 2003-2012. 10.1007/s00018-010-0616-z.CrossRefPubMed

14.

Nguyen TH, Liu J, Lombroso PJ: Striatal enriched phosphatase 61 dephosphorylates Fyn at phosphotyrosine 420. J Biol Chem. 2002, 277: 24274-24279. 10.1074/jbc.M111683200.CrossRefPubMed

15.

Resh MD: Fyn, a Src family tyrosine kinase. Int J Biochem Cell Biol. 1998, 30: 1159-1162. 10.1016/S1357-2725(98)00089-2.CrossRefPubMed

16.

Kennedy MB: Signal-processing machines at the postsynaptic density. Science. 2000, 290: 750-754. 10.1126/science.290.5492.750.CrossRefPubMed

17.

Nakazawa T, Komai S, Tezuka T, Hisatsune C, Umemori H, Semba K, Mishina M, Manabe T, Yamamoto T: Characterization of Fyn-mediated tyrosine phosphorylation sites on GluR epsilon 2 (NR2B) subunit of the N-methyl-D-aspartate receptor. J Biol Chem. 2001, 276: 693-699.CrossRefPubMed

18.

Kojima N, Ishibashi H, Obata K, Kandel ER: Higher seizure susceptibility and enhanced tyrosine phosphorylation of N-methyl-D-aspartate receptor subunit 2B in fyn transgenic mice. Learn Mem. 1998, 5: 429-445.PubMedCentralPubMed

19.

Grant SG, O’Dell TJ, Karl KA, Stein PL, Soriano P, Kandel ER: Impaired long-term potentiation, spatial learning, and hippocampal development in fyn mutant mice. Science. 1992, 258: 1903-1910. 10.1126/science.1361685.CrossRefPubMed

20.

Prybylowski K, Chang K, Sans N, Kan L, Vicini S, Wenthold RJ: The synaptic localization of NR2B-containing NMDA receptors is controlled by interactions with PDZ proteins and AP-2. Neuron. 2005, 47: 845-857. 10.1016/j.neuron.2005.08.016.PubMedCentralCrossRefPubMed

21.

Suzuki T, Okumura-Noji K: NMDA receptor subunits epsilon 1 (NR2A) and epsilon 2 (NR2B) are substrates for Fyn in the postsynaptic density fraction isolated from the rat brain. Biochem Biophys Res Commun. 1995, 216: 582-588. 10.1006/bbrc.1995.2662.CrossRefPubMed

22.

Malenka RC, Nicoll RA: Long-term potentiation – a decade of progress?. Science. 1999, 285: 1870-1874. 10.1126/science.285.5435.1870.CrossRefPubMed

23.

Massey PV, Johnson BE, Moult PR, Auberson YP, Brown MW, Molnar E, Collingridge GL, Bashir ZI: Differential roles of NR2A and NR2B-containing NMDA receptors in cortical long-term potentiation and long-term depression. J Neurosci. 2004, 24: 7821-7828. 10.1523/JNEUROSCI.1697-04.2004.CrossRefPubMed

24.

Isosaka T, Hattori K, Kida S, Kohno T, Nakazawa T, Yamamoto T, Yagi T, Yuasa S: Activation of Fyn tyrosine kinase in the mouse dorsal hippocampus is essential for contextual fear conditioning. Eur J Neurosci. 2008, 28: 973-981. 10.1111/j.1460-9568.2008.06405.x.CrossRefPubMed

25.

Lu YF, Kojima N, Tomizawa K, Moriwaki A, Matsushita M, Obata K, Matsui H: Enhanced synaptic transmission and reduced threshold for LTP induction in fyn-transgenic mice. Eur J Neurosci. 1999, 11: 75-82. 10.1046/j.1460-9568.1999.00407.x.CrossRefPubMed

26.

Babus LW, Little EM, Keenoy KE, Minami SS, Chen E, Song JM, Caviness J, Koo SY, Pak DT, Rebeck GW, Turner RS, Hoe HS: Decreased dendritic spine density and abnormal spine morphology in Fyn knockout mice. Brain Res. 2011, 1415: 96-102.PubMedCentralCrossRefPubMed

27.

Umemori H, Sato S, Yagi T, Aizawa S, Yamamoto T: Initial events of myelination involve Fyn tyrosine kinase signalling. Nature. 1994, 367: 572-576. 10.1038/367572a0.CrossRefPubMed

28.

Sperber BR, Boyle-Walsh EA, Engleka MJ, Gadue P, Peterson AC, Stein PL, Scherer SS, McMorris FA: A unique role for Fyn in CNS myelination. J Neurosci. 2001, 21: 2039-2047.PubMed

29.

Shirazi SK, Wood JG: The protein tyrosine kinase, fyn, in Alzheimer’s disease pathology. Neuroreport. 1993, 4: 435-437. 10.1097/00001756-199304000-00024.CrossRefPubMed

30.

Luo YQ, Hirashima N, Li YH, Alkon DL, Sunderland T, Etcheberrigaray R, Wolozin B: Physiological levels of beta-amyloid increase tyrosine phosphorylation and cytosolic calcium. Brain Res. 1995, 681: 65-74. 10.1016/0006-8993(95)00282-U.CrossRefPubMed

31.

Bamberger ME, Harris ME, McDonald DR, Husemann J, Landreth GE: A cell surface receptor complex for fibrillar beta-amyloid mediates microglial activation. J Neurosci. 2003, 23: 2665-2674.PubMed

32.

Grace EA, Busciglio J: Aberrant activation of focal adhesion proteins mediates fibrillar amyloid beta-induced neuronal dystrophy. J Neurosci. 2003, 23: 493-502.PubMed

33.

Klein WL, Krafft GA, Finch CE: Targeting small Aβ oligomers: the solution to an Alzheimer’s disease conundrum?. Trends Neurosci. 2001, 24: 219-224. 10.1016/S0166-2236(00)01749-5.CrossRefPubMed

34.

Lambert MP, Barlow AK, Chromy BA, Edwards C, Freed R, Liosatos M, Morgan TE, Rozovsky I, Trommer B, Viola KL, Wals P, Zhang C, Finch CE, Krafft GA, Klein WL: Diffusible, nonfibrillar ligands derived from Aβ_1–42 are potent central nervous system neurotoxins. Proc Natl Acad Sci U S A. 1998, 95: 6448-6453. 10.1073/pnas.95.11.6448.PubMedCentralCrossRefPubMed

35.

Chen S, Yadav SP, Surewicz WK: Interaction between human prion protein and amyloid-beta (Aβ) oligomers: role of N-terminal residues. J Biol Chem. 2010, 285: 26377-26383. 10.1074/jbc.M110.145516.PubMedCentralCrossRefPubMed

36.

Calella AM, Farinelli M, Nuvolone M, Mirante O, Moos R, Falsig J, Mansuy IM, Aguzzi A: Prion protein and Aβ-related synaptic toxicity impairment. EMBO Mol Med. 2010, 2: 306-314. 10.1002/emmm.201000082.PubMedCentralCrossRefPubMed

37.

Balducci C, Beeg M, Stravalaci M, Bastone A, Sclip A, Biasini E, Tapella L, Colombo L, Manzoni C, Borsello T, Chiesa R, Gobbi M, Salmona M, Forloni G: Synthetic amyloid-beta oligomers impair long-term memory independently of cellular prion protein. Proc Natl Acad Sci U S A. 2010, 107: 2295-2300. 10.1073/pnas.0911829107.PubMedCentralCrossRefPubMed

38.

Kessels HW, Nguyen LN, Nabavi S, Malinow R: The prion protein as a receptor for amyloid-beta. Nature. 2010, 466: E3-E4. 10.1038/nature09217. discussion E4–E5PubMedCentralCrossRefPubMed

39.

Cisse M, Sanchez PE, Kim DH, Ho K, Yu GQ, Mucke L: Ablation of cellular prion protein does not ameliorate abnormal neural network activity or cognitive dysfunction in the J20 line of human amyloid precursor protein transgenic mice. J Neurosci. 2011, 31: 10427-10431. 10.1523/JNEUROSCI.1459-11.2011.PubMedCentralCrossRefPubMed

40.

Resenberger UK, Harmeier A, Woerner AC, Goodman JL, Muller V, Krishnan R, Vabulas RM, Kretzschmar HA, Lindquist S, Hartl FU, Multhaup G, Winklhofer KF, Tatzelt J: The cellular prion protein mediates neurotoxic signalling of beta-sheet-rich conformers independent of prion replication. EMBO J. 2011, 30: 2057-2070. 10.1038/emboj.2011.86.PubMedCentralCrossRefPubMed

41.

Bate C, Williams A: Amyloid-beta-induced synapse damage is mediated via cross-linkage of cellular prion proteins. J Biol Chem. 2011, 286: 37955-37963. 10.1074/jbc.M111.248724.PubMedCentralCrossRefPubMed

42.

Alier K, Ma L, Yang J, Westaway D, Jhamandas JH: Aβ inhibition of ionic conductance in mouse basal forebrain neurons is dependent upon the cellular prion protein PrPC. J Neurosci. 2011, 31: 16292-16297. 10.1523/JNEUROSCI.4367-11.2011.CrossRefPubMed

43.

Chung E, Ji Y, Sun Y, Kascsak RJ, Kascsak RB, Mehta PD, Strittmatter SM, Wisniewski T: Anti-PrPC monoclonal antibody infusion as a novel treatment for cognitive deficits in an Alzheimer’s disease model mouse. BMC Neurosci. 2010, 11: 130-10.1186/1471-2202-11-130.PubMedCentralCrossRefPubMed

44.

Gimbel DA, Nygaard HB, Coffey EE, Gunther EC, Lauren J, Gimbel ZA, Strittmatter SM: Memory impairment in transgenic Alzheimer mice requires cellular prion protein. J Neurosci. 2010, 30: 6367-6374. 10.1523/JNEUROSCI.0395-10.2010.PubMedCentralCrossRefPubMed

45.

Kudo W, Lee HP, Zou WQ, Wang X, Perry G, Zhu X, Smith MA, Petersen RB, Lee HG: Cellular prion protein is essential for oligomeric amyloid-beta-induced neuronal cell death. Hum Mol Genet. 2012, 21: 1138-1144. 10.1093/hmg/ddr542.PubMedCentralCrossRefPubMed

46.

You H, Tsutsui S, Hameed S, Kannanayakal TJ, Chen L, Xia P, Engbers JD, Lipton SA, Stys PK, Zamponi GW: Aβ neurotoxicity depends on interactions between copper ions, prion protein, and N-methyl-D-aspartate receptors. Proc Natl Acad Sci U S A. 2012, 109: 1737-1742. 10.1073/pnas.1110789109.PubMedCentralCrossRefPubMed

47.

Zou WQ, Xiao X, Yuan J, Puoti G, Fujioka H, Wang X, Richardson S, Zhou X, Zou R, Li S, Zhu X, McGeer PL, McGeehan J, Kneale G, Rincon-Limas DE, Fernandez-Funez P, Lee HG, Smith MA, Petersen RB, Guo JP: Amyloid-beta42 interacts mainly with insoluble prion protein in the Alzheimer brain. J Biol Chem. 2011, 286: 15095-15105. 10.1074/jbc.M110.199356.PubMedCentralCrossRefPubMed

48.

Freir DB, Nicoll AJ, Klyubin I, Panico S, McDonald JM, Risse E, Asante EA, Farrow MA, Sessions RB, Saibil HR, Clarke AR, Rowan MJ, Walsh DM, Collinge J: Interaction between prion protein and toxic amyloid beta assemblies can be therapeutically targeted at multiple sites. Nat Commun. 2011, 2: 336-PubMedCentralCrossRefPubMed

49.

Barry AE, Klyubin I, McDonald JM, Mably AJ, Farrell MA, Scott M, Walsh DM, Rowan MJ: Alzheimer’s disease brain-derived amyloid-beta-mediated inhibition of LTP in vivo is prevented by immunotargeting cellular prion protein. J Neurosci. 2011, 31: 7259-7263. 10.1523/JNEUROSCI.6500-10.2011.CrossRefPubMed

50.

Salter MW, Kalia LV: Src kinases: a hub for NMDA receptor regulation. Nat Rev. 2004, 5: 317-328.CrossRef

51.

Lacor PN, Buniel MC, Furlow PW, Clemente AS, Velasco PT, Wood M, Viola KL, Klein WL: Aβ oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer’s disease. J Neurosci. 2007, 27: 796-807. 10.1523/JNEUROSCI.3501-06.2007.CrossRefPubMed

52.

Shankar GM, Li S, Mehta TH, Garcia-Munoz A, Shepardson NE, Smith I, Brett FM, Farrell MA, Rowan MJ, Lemere CA, Regan CM, Walsh DM, Sabatini BL, Selkoe DJ: Amyloid-beta protein dimers isolated directly from Alzheimer’s brains impair synaptic plasticity and memory. Nat Med. 2008, 14: 837-842. 10.1038/nm1782.PubMedCentralCrossRefPubMed

53.

Shankar GM, Bloodgood BL, Townsend M, Walsh DM, Selkoe DJ, Sabatini BL: Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. J Neurosci. 2007, 27: 2866-2875. 10.1523/JNEUROSCI.4970-06.2007.CrossRefPubMed

54.

Selkoe DJ: Alzheimer’s disease is a synaptic failure. Science. 2002, 298: 789-791. 10.1126/science.1074069.CrossRefPubMed

55.

Roberson ED, Scearce-Levie K, Palop JJ, Yan F, Cheng IH, Wu T, Gerstein H, Yu GQ, Mucke L: Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer’s disease mouse model. Science. 2007, 316: 750-754. 10.1126/science.1141736.CrossRefPubMed

56.

Bhaskar K, Hobbs GA, Yen SH, Lee G: Tyrosine phosphorylation of tau accompanies disease progression in transgenic mouse models of tauopathy. Neuropathol Appl Neurobiol. 2010, 36: 462-477. 10.1111/j.1365-2990.2010.01103.x.PubMedCentralCrossRefPubMed

57.

Bhaskar K, Yen SH, Lee G: Disease-related modifications in tau affect the interaction between Fyn and Tau. J Biol Chem. 2005, 280: 35119-35125. 10.1074/jbc.M505895200.CrossRefPubMed

58.

Lee G, Thangavel R, Sharma VM, Litersky JM, Bhaskar K, Fang SM, Do LH, Andreadis A, Van Hoesen G, Ksiezak-Reding H: Phosphorylation of tau by fyn: implications for Alzheimer’s disease. J Neurosci. 2004, 24: 2304-2312. 10.1523/JNEUROSCI.4162-03.2004.CrossRefPubMed

59.

Lee G, Newman ST, Gard DL, Band H, Panchamoorthy G: Tau interacts with src-family non-receptor tyrosine kinases. J Cell Sci. 1998, 111: 3167-3177.PubMed

60.

Roberson ED, Halabisky B, Yoo JW, Yao J, Chin J, Yan F, Wu T, Hamto P, Devidze N, Yu GQ, Palop JJ, Noebels JL, Mucke L: Amyloid-beta/Fyn-induced synaptic, network, and cognitive impairments depend on tau levels in multiple mouse models of Alzheimer’s disease. J Neurosci. 2011, 31: 700-711. 10.1523/JNEUROSCI.4152-10.2011.PubMedCentralCrossRefPubMed

61.

Ittner LM, Ke YD, Delerue F, Bi M, Gladbach A, van Eersel J, Wolfing H, Chieng BC, Christie MJ, Napier IA, Eckert A, Staufenbiel M, Hardeman E, Götz J: Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer’s disease mouse models. Cell. 2010, 142: 387-397. 10.1016/j.cell.2010.06.036.CrossRefPubMed

62.

Cruchaga C, Kauwe JS, Mayo K, Spiegel N, Bertelsen S, Nowotny P, Shah AR, Abraham R, Hollingworth P, Harold D, Owen MM, Williams J, Lovestone S, Peskind ER, Li G, Leverenz JB, Galasko D, Morris JC, Fagan AM, Holtzman DM, Goate AM, Alzheimer’s Disease Neuroimaging Initiative: SNPs associated with cerebrospinal fluid phospho-tau levels influence rate of decline in Alzheimer’s disease. PLoS Genet. 2010, 6: e1001101-10.1371/journal.pgen.1001101.PubMedCentralCrossRefPubMed

63.

Bekris LM, Millard S, Lutz F, Li G, Galasko DR, Farlow MR, Quinn JF, Kaye JA, Leverenz JB, Tsuang DW, Yu CE, Peskind ER: Tau phosphorylation pathway genes and cerebrospinal fluid tau levels in Alzheimer’s disease. Am J Med Genet B Neuropsychiatr Genet. 2012, 159B: 874-883. 10.1002/ajmg.b.32094.CrossRefPubMed

64.

Chin J, Palop JJ, Yu GQ, Kojima N, Masliah E, Mucke L: Fyn kinase modulates synaptotoxicity, but not aberrant sprouting, in human amyloid precursor protein transgenic mice. J Neurosci. 2004, 24: 4692-4697. 10.1523/JNEUROSCI.0277-04.2004.CrossRefPubMed

65.

Chin J, Palop JJ, Puolivali J, Massaro C, Bien-Ly N, Gerstein H, Scearce-Levie K, Masliah E, Mucke L: Fyn kinase induces synaptic and cognitive impairments in a transgenic mouse model of Alzheimer’s disease. J Neurosci. 2005, 25: 9694-9703. 10.1523/JNEUROSCI.2980-05.2005.CrossRefPubMed

66.

Minami SS, Clifford TG, Hoe HS, Matsuoka Y, Rebeck GW: Fyn knock-down increases Abeta, decreases phospho-tau, and worsens spatial learning in 3xTg-AD mice. Neurobiol Aging. 2012, 33: 825-e15–e24PubMedCentralCrossRefPubMed

67.

Zhang Y, Kurup P, Xu J, Carty N, Fernandez SM, Nygaard HB, Pittenger C, Greengard P, Strittmatter SM, Nairn AC, Lombroso PJ: Genetic reduction of striatal-enriched tyrosine phosphatase (STEP) reverses cognitive and cellular deficits in an Alzheimer’s disease mouse model. Proc Natl Acad Sci U S A. 2010, 107: 19014-19019. 10.1073/pnas.1013543107.PubMedCentralCrossRefPubMed

68.

Dhawan G, Combs CK: Inhibition of Src kinase activity attenuates amyloid associated microgliosis in a murine model of Alzheimer’s disease. J Neuroinflamm. 2012, 9: 117-10.1186/1742-2094-9-117.CrossRef

69.

Baer AS, Syed YA, Kang SU, Mitteregger D, Vig R, Ffrench-Constant C, Franklin RJ, Altmann F, Lubec G, Kotter MR: Myelin-mediated inhibition of oligodendrocyte precursor differentiation can be overcome by pharmacological modulation of Fyn-RhoA and protein kinase C signalling. Brain. 2009, 132: 465-481.PubMedCentralCrossRefPubMed

70.

Appleby MW, Gross JA, Cooke MP, Levin SD, Qian X, Perlmutter RM: Defective T cell receptor signaling in mice lacking the thymic isoform of p59fyn. Cell. 1992, 70: 751-763. 10.1016/0092-8674(92)90309-Z.CrossRefPubMed

71.

Tamura T, Igarashi O, Hino A, Yamane H, Aizawa S, Kato T, Nariuchi H: Impairment in the expression and activity of Fyn during differentiation of naive CD4⁺ T cells into the Th2 subset. J Immunol. 2001, 167: 1962-1969.CrossRefPubMed

72.

Reddy KB, Smith DM, Plow EF: Analysis of Fyn function in hemostasis and alphaIIbbeta3-integrin signaling. J Cell Sci. 2008, 121: 1641-1648. 10.1242/jcs.014076.PubMedCentralCrossRefPubMed

73.

Piette F, Belmin J, Vincent H, Schmidt N, Pariel S, Verny M, Marquis C, Mely J, Hugonot-Diener L, Kinet JP, Dubreuil P, Moussy A, Hermine O: Masitinib as an adjunct therapy for mild-to-moderate Alzheimer’s disease: a randomised, placebo-controlled phase 2 trial. Alzheimers Res Ther. 2011, 3: 16-10.1186/alzrt75.PubMedCentralCrossRefPubMed

74.

Hennequin LF, Allen J, Breed J, Curwen J, Fennell M, Green TP, Lambert-van der Brempt C, Morgentin R, Norman RA, Olivier A, Otterbein L, Plé PA, Warin N, Costello G: N-(5-chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5-(tetrahydro-2H-pyran-4-yloxy)quinazolin-4-amine, a novel, highly selective, orally available, dual-specific c-Src/Abl kinase inhibitor. J Med Chem. 2006, 49: 6465-6488. 10.1021/jm060434q.CrossRefPubMed

75.

Gangadhar TC, Clark JI, Karrison T, Gajewski TF: Phase II study of the Src kinase inhibitor saracatinib (AZD0530) in metastatic melanoma. Invest New Drugs. 2013, 31: 769-773. 10.1007/s10637-012-9897-4.PubMedCentralCrossRefPubMed

76.

Gucalp A, Sparano JA, Caravelli J, Santamauro J, Patil S, Abbruzzi A, Pellegrino C, Bromberg J, Dang C, Theodoulou M, Massague J, Norton L, Hudis C, Traina TA: Phase II trial of saracatinib (AZD0530), an oral SRC-inhibitor for the treatment of patients with hormone receptor-negative metastatic breast cancer. Clin Breast Cancer. 2011, 11: 306-311. 10.1016/j.clbc.2011.03.021.PubMedCentralCrossRefPubMed

77.

Mackay HJ, Au HJ, McWhirter E, Alcindor T, Jarvi A, MacAlpine K, Wang L, Wright JJ, Oza AM: A phase II trial of the Src kinase inhibitor saracatinib (AZD0530) in patients with metastatic or locally advanced gastric or gastro esophageal junction (GEJ) adenocarcinoma: a trial of the PMH phase II consortium. Invest New Drugs. 2012, 30: 1158-1163. 10.1007/s10637-011-9650-4.CrossRefPubMed

78.

Fury MG, Baxi S, Shen R, Kelly KW, Lipson BL, Carlson D, Stambuk H, Haque S, Pfister DG: Phase II study of saracatinib (AZD0530) for patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). Anticancer Res. 2011, 31: 249-253.PubMedCentralPubMed

79.

Renouf DJ, Moore MJ, Hedley D, Gill S, Jonker D, Chen E, Walde D, Goel R, Southwood B, Gauthier I, Walsh W, McIntosh L, Seymour L: A phase I/II study of the Src inhibitor saracatinib (AZD0530) in combination with gemcitabine in advanced pancreatic cancer. Invest New Drugs. 2012, 30: 779-786. 10.1007/s10637-010-9611-3.CrossRefPubMed

Titel: Fyn kinase inhibition as a novel therapy for Alzheimer’s disease
verfasst von: Haakon B Nygaard
Christopher H van Dyck
Stephen M Strittmatter
Publikationsdatum: 01.02.2014
Verlag: BioMed Central
Erschienen in: Alzheimer's Research & Therapy / Ausgabe 1/2014
Elektronische ISSN: 1758-9193
DOI: https://doi.org/10.1186/alzrt238

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

25.04.2024 | Hypotonie | Nachrichten

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Fyn kinase inhibition as a novel therapy for Alzheimer’s disease

Abstract

Leitlinien kompakt für die Neurologie

Neu im Fachgebiet Neurologie

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Demenzkranke durch Antipsychotika vielfach gefährdet

Parkinson-Therapie im Wandel – aktuelle Leitlinie im Fokus

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

Update Neurologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2014

Amyloid-beta 42 adsorption following serial tube transfer

Open questions for Alzheimer’s disease immunotherapy

Active immunotherapy options for Alzheimer’s disease

Assessing THK523 selectivity for tau deposits in Alzheimer’s disease and non–Alzheimer’s disease tauopathies

Histone deacetylase 6 inhibition improves memory and reduces total tau levels in a mouse model of tau deposition

Chronic traumatic encephalopathy: a spectrum of neuropathological changes following repetitive brain trauma in athletes and military personnel

Leitlinien kompakt für die Neurologie

Neu im Fachgebiet Neurologie

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Demenzkranke durch Antipsychotika vielfach gefährdet

Parkinson-Therapie im Wandel – aktuelle Leitlinie im Fokus

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

Update Neurologie